Key Takeaways:
- FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B compounding facilities
- Move would end large-scale production of compounded GLP-1s costing $200-400 monthly vs $1000+ for brand drugs
- Public comment period open through June 30, 2026, before final decision
- Manufacturers now offer direct-pay programs at $499/month for FDA-approved versions
FDA Takes Decisive Action Against Compounded GLP-1 Supply
The U.S. Food and Drug Administration on April 30, 2026, announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The proposal represents what may be the final regulatory blow to the compounded GLP-1 industry that has provided affordable alternatives to millions of people.
If finalized, the rule would prohibit 503B outsourcing facilities from compounding these agents from bulk substances under any circumstances, regardless of future market conditions. The FDA carefully reviewed the nominations it received and did not identify sufficient evidence to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances.
For anyone currently using compounded semaglutide or tirzepatide, this proposal signals a major shift in how you'll access these medications moving forward.
From Shortage Solution to Regulatory Crackdown
The compounded GLP-1 market emerged from necessity in 2022 when skyrocketing demand outpaced manufacturing capacity. Semaglutide and tirzepatide were both added to the shortage list in 2022 due to surging demand, as was liraglutide. The resulting compounding market offered access to these agents at $150 to $300 per month, compared with brand-name costs that exceeded $1000.
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, establishing phased enforcement deadlines for compounders to wind down operations. The Outsourcing Facilities Association filed federal lawsuits challenging both determinations, but courts denied preliminary injunctions in each case, and the enforcement deadlines held.
What started as a temporary solution during drug shortages has evolved into a thriving market serving people who couldn't afford brand-name versions. Now that chapter appears to be closing permanently.
Safety Concerns Drive FDA's Decision
As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials—some of which required hospitalization. Concerns about counterfeit products entering the market through online channels have further reinforced the FDA's enforcement focus.
"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," FDA Commissioner Marty Makary said in the agency's announcement. This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input.
The regulatory shift prioritizes safety and standardization, but it comes at the cost of affordability for many people who have relied on compounded alternatives.
The Cost Reality: Returning to $1000+ Monthly Treatments
The regulatory shift forces people back to brand-name medications with dramatically higher costs. With brand-name versions like Wegovy, Ozempic, and Mounjaro, often priced at more than $1,000 per month and limited insurance coverage, compounded versions of these agents have filled a temporary but vital gap, with compounded formulations often costing between $250 and $400 per month.
For the uninsured, underinsured, or those denied coverage based on therapeutic indication, compounded medications are the only realistic option. Now, many people are facing difficult choices. Some are stretching doses, skipping injections, or turning to non-regulated online sources and international pharmacies. Others have stopped therapy despite documented benefits in weight reduction, glycemic control, and overall quality of life.
This price difference represents a significant barrier that could force many people to discontinue their treatment entirely. The gap between $300 compounded medications and $1000+ brand names creates real hardship for families already managing tight budgets.
Manufacturers Introduce New Direct-Pay Programs
As compounded alternatives disappear, pharmaceutical companies have launched direct-pay programs to bridge the affordability gap. Novo Nordisk has introduced the NovoCare Pharmacy, offering all doses of its FDA-approved weight-loss drug, Wegovy (semaglutide), at a reduced cost of $499 per month for cash-paying customers. This initiative includes convenient home delivery, making authentic, FDA-approved Wegovy more accessible and affordable.
Lilly's LillyDirect program has been active for a year making Zepbound available for a cash price, offering access to telehealth and then connecting people into an online pharmacy. In February 2025 LillyDirect began offering a wider range of doses and brought prices down to approximately $499 per month.
While these programs don't match compounded pricing, they represent a significant reduction from standard retail costs and provide guaranteed quality and consistency.
What This Means for You
If you're currently using compounded GLP-1 medications, this proposal signals the end of that pathway once it's finalized. Public comments must be submitted by June 30, 2026, but the regulatory momentum appears decisive.
Your next steps should include exploring brand-name manufacturer savings programs and comparing costs across different options. Many people qualify for significant discounts through Novo Nordisk and Eli Lilly programs, potentially bringing monthly costs down to $25-50 with commercial insurance. For those paying cash, the new direct-pay programs offer FDA-approved medications at $499 monthly—still higher than compounded alternatives, but with guaranteed quality and consistency.
Consider browsing telehealth providers that work directly with manufacturer programs to find the most affordable legitimate options. Some providers have partnerships that can help reduce your overall treatment costs beyond the medication itself.
For pharmacists, the practical message is clear: compounded GLP-1s are not an appropriate routine substitute when FDA-approved therapies are commercially available. Community pharmacists should be prepared to counsel people still seeking lower-cost alternatives and help them identify manufacturer savings programs.
Don't wait until the final rule takes effect. Start exploring your options now to ensure continuity of care and find the most affordable path forward for your specific situation.
Sources
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List - Official FDA announcement
- Federal Register Notice - Detailed regulatory proposal and rationale
- FDA Moves to Permanently Close the Door on Compounded GLP-1s - Pharmacy Times analysis
- Navigating Access: The Future of Compounded GLP-1 Receptor Agonists for Weight Loss - PMC research on access and cost impacts